| Slide Lecture Programs |
| 2006 Core Curriculum |
| Antiplatelet Interventions in ACS |
March 10, 2006
|
| III: |
ACC/AHA UA/NSTEMI Guidelines: Role of GP IIb/IIIa Inhibitors" width="220" height="147" border="0">
ACC/AHA UA/NSTEMI Guidelines: Role of GP IIb/IIIa Inhibitors
|
|
 |
|
 |
|
 |
28 |
 |
| |

ACC/AHA guidelines for UA/NSTEMI: GP IIb/IIIa inhibitors
|
|
 |
|
 |
|
 |
29 |
 |
| |

ACC/AHA UA/NSTEMI Guidelines: Management of high-risk patients
|
|
 |
|
 |
|
 |
30 |
 |
| |

Mortality risk is lower with early (<24-hour) GP IIb/IIIa inhibition
|
|
 |
|
 |
|
 |
31 |
 |
| |

Recommended therapies for UA/NSTEMI
|
|
 |
|
 |
|
 |
32 |
 |
| |

Majority of ACS patients undergo catheterization
|
|
 |
|
 |
|